Clinical trials: Papulopustular Rosacea (PPR)
Papulopustular Rosacea (PPR)
Phase 3 Papulopustular Rosacea Study
The purpose of this study is to demonstrate that CD5024 1% cream is more effective than its vehicle when applied once daily, at bed time, during a 12 week period in subjects with Papulopustular Rosacea (PPR) and continues to be…
- Trial name
- NCT01493687
- Testing
- CD5024, Azelaic acid 15% Gel
- Where
- 50 sites in United States, Canada
- Volunteers
- 683 people
- Sponsor
- Galderma R&D
Papulopustular Rosacea
CD5024 1% [Ivermectin 1%] Cream Versus Metronidazole 0.75% Cream in Papulopustular Rosacea (PPR) Study
Study objectives: To compare efficacy and safety of Ivermectin 1% cream versus metronidazole 0.75% cream in subjects with papulopustular rosacea after 16-week topical treatment.
- Trial name
- ATTRACT (NCT01493947)
- Testing
- Ivermectin 1% cream, Metronidazole 0.75% cream
- Where
- 60 sites in Bulgaria, Czechia and 8 more
- Volunteers
- 962 people
- Sponsor
- Galderma R&D
Papulopustular Rosacea
Phase 3 Papulopustular Rosacea Study
The purpose of this study is to demonstrate that CD5024 1% cream is more effective than its vehicle when applied once daily, at bed time, during a 12 week period in subjects with Papulopustular Rosacea (PPR) and continues to be…
- Trial name
- NCT01494467
- Testing
- CD5024, Azelaic acid 15% Gel
- Where
- 50 sites in United States, Canada
- Volunteers
- 688 people
- Sponsor
- Galderma R&D